What to expect from PGT-M for a thalassaemia carrier

Being a thalassaemia carrier does not by itself mean that you have thalassaemia disease. The reproductive implications depend on the exact gene change and the other biological parent's result, so a genetics team should interpret the reports together.

PGT-M tests embryo cells for the specific familial changes selected in advance. It may identify embryos affected by the targeted condition or embryos carrying a change, depending on the test design and the couple's goals. It does not check every genetic or pregnancy problem.

Bring haemoglobinopathy reports, partner testing and family records to genetic counselling. The team may need to confirm the gene variants and build a laboratory test before IVF begins. Treatment commonly involves ovarian stimulation, egg collection, fertilisation, embryo development, biopsy and laboratory analysis.

Before treatment, ask how results will be described, how embryos are prioritised for transfer, and whether prenatal testing will be offered to confirm the embryo result. Discuss other reproductive choices without pressure.

During IVF, seek urgent clinical advice for severe pain, heavy bleeding, fainting, fever, breathing difficulty or rapidly increasing abdominal swelling. Once pregnant, contact your maternity team about bleeding, significant pain or any concern, and attend the recommended genetic and antenatal appointments.

Which gene changes do we carry, and what inheritance pattern applies to us? What will the PGT-M report show? Is confirmatory testing in pregnancy recommended? What happens if no embryo matches our agreed plan?